The FDA has approved the popular drug Dupixent (generic name, dupilumab) for adults and kids 12 and up with chronic ...

Eliminated the link between adipose tissue inflammation induced by LDL, or other metabolic and microbial inflammatory triggers, with several risk factors for type 2 diabetes and cardiovascular ...

The FDA has approved Dupixent as the first new targeted therapy in over ten years for chronic spontaneous urticaria in patients aged 12 and older who remain symptomatic despite antihistamine treatment ...

Experiments in mice infected with the SARS-CoV-2 virus revealed that the immune cell class in question, called nerve and ...

Chronic spontaneous urticaria is chronic inflammatory skin disease driven in part by type 2 inflammation, which causes sudden and debilitating hives and recurring itch.

Researchers identified a direct connection between cancer-related inflammation and the loss of motivation characteristic of advanced cancer. In a mouse study, they describe a brain pathway that starts ...

Approval based on Phase 3 trials demonstrating Dupixent significantly reduced itch and hives compared to placebo In the U.S., there are more than ...